No Data
No Data
Does NeoGenomics (NASDAQ:NEO) Have A Healthy Balance Sheet?
NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), Trevi Therapeutics (TRVI) and DENTSPLY SIRONA (XRAY)
BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Announces Target Price $18
NeoGenomics Hold Rating Maintained Amidst Ongoing Legal Challenges and MRD Assay Development Uncertainty
Needham Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $19
Needham analyst Michael Matson maintains $NeoGenomics(NEO.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate of 43.6% and a